New drug cocktail aims to wipe out stomach tumors before surgery
NCT ID NCT07151209
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 33 times
Summary
This study tests whether a combination of two immunotherapy drugs (Iparomlimab and Tuvonralimab) plus chemotherapy and a targeted therapy can shrink locally advanced stomach or gastroesophageal junction cancer in patients with specific genetic markers (MSI-H/dMMR). The goal is to make the tumor removable by surgery and achieve a complete response. About 20 adults who have not had prior treatment for advanced disease will participate.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.